$0.02
(Market cap
$3 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-8.9 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
15.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-13.9
-
Face value
--
-
Shares outstanding
5,210,465
10 Years Aggregate
CFO
$-69.68 Mln
EBITDA
$-77.77 Mln
Net Profit
$-77.25 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
GeoVax Labs (GOVX)
| -84.7 | -10.5 | -81.2 | -96.7 | -85.4 | -80.1 | -87.4 |
|
BSE Sensex
| -9.1 | 1.1 | 1.2 | -4.8 | 5.8 | 6.6 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
GeoVax Labs (GOVX)
| -93.1 | -54.1 | -42.7 | -82.6 | 7.1 | -71.8 | -100.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
GeoVax Labs (GOVX)
|
0.7 | 3.4 | 0.0 | -20.4 | -- | -731.3 | -- | 1.8 |
| 88.3 | 12,304.7 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.4 | |
| 249.3 | 16,614.0 | 1,054.4 | 755.9 | 5.7 | -- | 19.4 | 10.1 | |
| 78.8 | 10,682.6 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 55.5 | 13,400.0 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 106.8 | 12,277.1 | 1,663.7 | 413.6 | 36.3 | 430 | 31.2 | 83.9 | |
| 538.1 | 11,938.8 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.9 | |
| 616.0 | 17,326.2 | 2,782.3 | 491.5 | 21.1 | 110.1 | 36.5 | 39.4 | |
| 371.0 | 10,496.2 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 150.6 | 9,985.8 | 282.0 | 82.9 | -28.6 | 11.4 | 147 | 11.6 |
Shareholding Pattern
View DetailsAbout GeoVax Labs (GOVX)
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine... candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia. Read more
-
Chairman, President & CEO
Mr. David Alan Dodd
-
Chairman, President & CEO
Mr. David Alan Dodd
-
Headquarters
Smyrna, GA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for GeoVax Labs (GOVX)
What is the current share price of GeoVax Labs Inc (GOVX) Today?
The share price of GeoVax Labs Inc (GOVX) is $0.65 (NASDAQ) as of 27-Aug-2026 11:37 EDT. GeoVax Labs Inc (GOVX) has given a return of -85.39% in the last 3 years.
What is the current PB & PE ratio of GeoVax Labs Inc (GOVX)?
Since, TTM earnings of GeoVax Labs Inc (GOVX) is negative, P/E ratio is not available.
The P/B ratio of GeoVax Labs Inc (GOVX) is 1.77 times as on 21-Aug-2026, a 67 discount to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.01 |
0.08 |
2024 |
-1.04 |
5.16 |
2023 |
-0.03 |
0.11 |
2022 |
-0.08 |
0.04 |
2021 |
-0.08 |
0.35 |
What is the 52 Week High and Low of GeoVax Labs Inc (GOVX)?
The 52-week high and low of GeoVax Labs Inc (GOVX) are Rs 107.88 and Rs 0.59 as of 27-Aug-2026.
What is the market cap of GeoVax Labs Inc (GOVX)?
GeoVax Labs Inc (GOVX) has a market capitalisation of $ 3 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in GeoVax Labs Inc (GOVX)?
Before investing in GeoVax Labs Inc (GOVX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.